These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33385363)

  • 1. Susceptibility to paromomycin in clinical isolates and reference strains of Leishmania species responsible for tegumentary leishmaniasis in Brazil.
    Coser EM; Ferreira BA; Yamashiro-Kanashiro EH; Lindoso JAL; Coelho AC
    Acta Trop; 2021 Mar; 215():105806. PubMed ID: 33385363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro miltefosine and amphotericin B susceptibility of strains and clinical isolates of Leishmania species endemic in Brazil that cause tegumentary leishmaniasis.
    Ferreira BA; Coser EM; Saborito C; Yamashiro-Kanashiro EH; Lindoso JAL; Coelho AC
    Exp Parasitol; 2023 Mar; 246():108462. PubMed ID: 36642298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo.
    Coser EM; Ferreira BA; Branco N; Yamashiro-Kanashiro EH; Lindoso JAL; Coelho AC
    Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():91-98. PubMed ID: 33011651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphotericin B resistance in Leishmania amazonensis: In vitro and in vivo characterization of a Brazilian clinical isolate.
    Ferreira BA; Coser EM; de la Roca S; Aoki JI; Branco N; Soares GHC; Lima MIS; Coelho AC
    PLoS Negl Trop Dis; 2024 May; 18(5):e0012175. PubMed ID: 38768213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of
    Özbilgin A; Çavuş İ; Kaya T; Yıldırım A; Harman M
    Turkiye Parazitol Derg; 2020 Mar; 44(1):12-16. PubMed ID: 32212583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model.
    Utaile M; Kassahun A; Abebe T; Hailu A
    Exp Parasitol; 2013 May; 134(1):68-75. PubMed ID: 23434530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
    Arevalo J; Ramirez L; Adaui V; Zimic M; Tulliano G; Miranda-Verástegui C; Lazo M; Loayza-Muro R; De Doncker S; Maurer A; Chappuis F; Dujardin JC; Llanos-Cuentas A
    J Infect Dis; 2007 Jun; 195(12):1846-51. PubMed ID: 17492601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
    Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
    Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
    Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
    J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro interaction between paromomycin sulphate and four drugs with leishmanicidal activity against three New World Leishmania species.
    de Morais-Teixeira E; Gallupo MK; Rodrigues LF; Romanha AJ; Rabello A
    J Antimicrob Chemother; 2014 Jan; 69(1):150-4. PubMed ID: 23970484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?
    Yardley V; Ortuno N; Llanos-Cuentas A; Chappuis F; Doncker SD; Ramirez L; Croft S; Arevalo J; Adaui V; Bermudez H; Decuypere S; Dujardin JC
    J Infect Dis; 2006 Oct; 194(8):1168-75. PubMed ID: 16991093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Sensitivity of Cutaneous
    Ginouvès M; Simon S; Nacher M; Demar M; Carme B; Couppié P; Prévot G
    Am J Trop Med Hyg; 2017 May; 96(5):1143-1150. PubMed ID: 28167598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro selection of ketoconazole-pentamidine-resistant Leishmania (Viannia) braziliensis strains.
    Salazar-Villamizar ME; Escobar P
    Exp Parasitol; 2022 Feb; 233():108206. PubMed ID: 34973293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
    Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
    Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis.
    Gonçalves GS; Fernandes AP; Souza RC; Cardoso JE; de Oliveira-Silva F; Maciel FC; Rabello A; Ferreira LA
    Acta Trop; 2005 Feb; 93(2):161-7. PubMed ID: 15652330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Biological Characterization of Leishmania (Viannia) guyanensis Isolated from a Patient with Tegumentary Leishmaniasis in Goiás, a Nonendemic Area for This Species in Brazil.
    Pires Ada S; Borges AF; Cappellazzo Coelho A; Dorta ML; Lino Junior Rde S; Pereira LI; Pinto SA; Pelli de Oliveira MA; de Matos GG; Abrahamsohn IA; Uliana SR; Lima GM; Ribeiro-Dias F
    Biomed Res Int; 2015; 2015():350764. PubMed ID: 26583102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B.
    Zauli-Nascimento RC; Miguel DC; Yokoyama-Yasunaka JK; Pereira LI; Pelli de Oliveira MA; Ribeiro-Dias F; Dorta ML; Uliana SR
    Trop Med Int Health; 2010 Jan; 15(1):68-76. PubMed ID: 19874570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria.
    Eddaikra N; Ait-Oudhia K; Kherrachi I; Oury B; Moulti-Mati F; Benikhlef R; Harrat Z; Sereno D
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006310. PubMed ID: 29561842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.
    Coelho AC; Trinconi CT; Costa CH; Uliana SR
    PLoS Negl Trop Dis; 2014 Jul; 8(7):e2999. PubMed ID: 25033218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.